A detailed history of Balyasny Asset Management LLC transactions in Insmed Inc stock. As of the latest transaction made, Balyasny Asset Management LLC holds 20,815 shares of INSM stock, worth $1.36 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
20,815
Previous 160,747 87.05%
Holding current value
$1.36 Million
Previous $10.8 Million 85.9%
% of portfolio
0.0%
Previous 0.02%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$62.0 - $79.01 $8.68 Million - $11.1 Million
-139,932 Reduced 87.05%
20,815 $1.52 Million
Q2 2024

Aug 14, 2024

SELL
$22.0 - $69.71 $6.37 Million - $20.2 Million
-289,647 Reduced 64.31%
160,747 $10.8 Million
Q1 2024

May 13, 2024

SELL
$25.72 - $29.94 $12.7 Million - $14.8 Million
-493,037 Reduced 52.26%
450,394 $12.2 Million
Q4 2023

Feb 14, 2024

BUY
$23.42 - $31.74 $20.2 Million - $27.4 Million
862,055 Added 1059.35%
943,431 $29.2 Million
Q3 2023

Nov 14, 2023

SELL
$19.86 - $26.93 $18.1 Million - $24.6 Million
-912,682 Reduced 91.81%
81,376 $2.05 Million
Q2 2023

Aug 14, 2023

BUY
$16.44 - $21.1 $16.3 Million - $21 Million
994,058 New
994,058 $21 Million
Q4 2022

Feb 14, 2023

BUY
$16.98 - $23.15 $2.95 Million - $4.02 Million
173,618 Added 83.06%
382,651 $7.65 Million
Q3 2022

Nov 14, 2022

SELL
$20.88 - $28.21 $5.94 Million - $8.02 Million
-284,298 Reduced 57.63%
209,033 $4.5 Million
Q2 2022

Aug 15, 2022

BUY
$17.07 - $25.71 $8.42 Million - $12.7 Million
493,331 New
493,331 $9.73 Million
Q1 2019

May 15, 2019

SELL
$13.91 - $31.15 $367,168 - $822,235
-26,396 Closed
0 $0
Q4 2018

Feb 14, 2019

BUY
$11.6 - $18.7 $614 - $991
53 Added 0.2%
26,396 $346,000
Q3 2018

Nov 14, 2018

BUY
$18.95 - $28.08 $499,199 - $739,711
26,343 New
26,343 $533,000

Others Institutions Holding INSM

About INSMED Inc


  • Ticker INSM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 135,476,992
  • Market Cap $8.84B
  • Description
  • Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversibl...
More about INSM
Track This Portfolio

Track Balyasny Asset Management LLC Portfolio

Follow Balyasny Asset Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Balyasny Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Balyasny Asset Management LLC with notifications on news.